H.u.group Holdings, Inc. · TSE:4544

H.u.group — Q1 FY2025 Earnings Presentation

15 slides from H.u.group's earnings presentation, Aug 8, 2025

  1. Slide 1: Financial Results for the First Quarter of FY2025 (Ended June 30, 2025)

    Financial Results for The First Quarter of FY2025 (Ended June 30, 2025) Aug. 8, 2025 (TSE: 4544)

  2. Slide 2: Notes & references

    Notes & references: * The financial information in this document follows Japanese GAAP, with the exception for EBITDA (Operating Profit + Depreciation + Goodwill Impairment), which is a non-GAAP measure. * In some cases, “Net profit/loss attributable to shareholders of the parent company” may be abb

  3. Slide 3: Executive Summary

    Executive Summary The • Operating profit: ¥0.87 B, on track with the plan • +¥0.25 B YoY, and +¥0.89 B QoQ Group • Pro forma operating profit: ¥1.34 B (excluding M&A expenses of ¥0.47 B) • Genetic testing and esoteric testing: ongoing growth • Marginal profit growth driven 1 mainly by service and pr

  4. Slide 4: Consolidated Results for FY2025 Q1

    Consolidated Results for FY2025 Q1 (¥ billion) FY2024 Q1 FY2025 Q1 Profit Profit Change Results Results ratio ratio Net sales 59.47 61.40 +1.93 +3.2% LTS 37.70 39.30 +1.60 +4.2% IVD 14.42 14.10 -0.32 -2.2% HS 7.34 7.99 +0.65 +8.9% EBITDA 5.68 9.6% 6.31 10.3% +0.63 +11.0% LTS 1.39 3.7% 2.62 6.7% +1.2

  5. Slide 5: Consolidated Net Sales Changes

    Consolidated Net Sales Changes (¥ billion) 65 +1.60 -0.32 +0.65 61.40 60 59.47 55 0 50 FY24 LTS IVD HS FY25 Q1 Q1 4

  6. Slide 6: Consolidated Operating Profit Changes

    Consolidated Operating Profit Changes (¥ billion) 2.0 (-) Occurrence of M&A related costs 1.5 +0.84 -0.62 M&A related costs +0.23 -0.19 -0.47 1.0 0.87 0.62 0.5 (+) Profit increase driven by sales growth (+) Marginal profit increase by service and pricing optimization, etc 0.0 FY24 LTS IVD HS H.U. FY

  7. Slide 7: Quarterly Performance

    Quarterly Performance Net sales EBITDA, OP (¥ billion) Net sales related to (¥ billion) Net sales 1 EBITDA Operating Profit 90 COVID-19 testing 45 68.8 66.9 65.3 59.9 59.9 61.0 59.4 59.5 60.5 62.1 61.0 61.4 60 12.3 15.0 11.4 56.6 3.2 2.1 1.9 1.5 0.7 30 4.0 2.5 1.5 6.4 2.9 60.1 59.5 60.7 57.8 57.0 58

  8. Slide 8: Consolidated Ordinary Profit/Loss & Net Profit/Loss

    Consolidated Ordinary Profit/Loss & Net Profit/Loss Ordinary Profit/Loss Net Profit/Loss (¥ billion) (¥ billion) 1.0 1.0 0.64 0.5 0.5 0.18 -0.49 -1.20 0.0 0.0 -0.5 -0.5 -1.0 -1.0 -1.5 -1.5 FY24 Q1 FY25 Q1 FY24 Q1 FY25 Q1 Major non-operating factors Major factors affected to net profit ・Foreign excha

  9. Slide 9: LTS

    LTS Quarterly Results YoY Comparison Net sales EBITDA, OP (¥ billion) (¥ billion) (¥ billion) 50 20 FY24_Q1 FY25_Q1 Change Net sales 37.70 39.30 +1.60 +4.2% 38.8 38.5 38.0 39.3 Off-site 30.89 32.68 +1.78 +5.8% 37.7 1.1 1.0 0.7 FMS/Branch 6.09 5.94 -0.15 -2.5% 0.7 1.0 6.3 5.9 Others 0.72 0.68 -0.03 -

  10. Slide 10: IVD

    IVD Quarterly Results YoY Comparison Net sales EBITDA, OP (¥ billion) (¥ billion) (¥ billion) 20 16 FY24_Q1 FY25_Q1 Change Net sales 14.42 14.10 -0.32 -2.2% Lumipulse 5.99 6.47 +0.49 +8.2% 16.1 15.4 Japan 4.73 4.46 -0.27 -5.6% 14.4 14.6 14.1 Overseas 1.26 2.01 +0.76 +60.1% 2.3 2.2 CDMO etc. 6.30 6.0

  11. Slide 11: IVD Topics 1: NEURO

    IVD Topics 1：NEURO Lumipulse NEURO Reagent Sales Global Regulatory Status  Plasma reagent growth leading NEURO  U.S: FDA approved on May 16 reagent sales  Plasma pTau217/ß-Amyloid 1-42 ratio reagent  Sales growth driven mainly by U.S. and EU markets  World’s first Plasma pTau217 reagent to aid

  12. Slide 12: IVD Topics 2: M&A

    IVD Topics 2：M&A Business Overview Strategic significance  Company Name：Plasma Services Group (PSG)  Advancing the CDMO business  Foundation： 2004 「Contents Expansion」 × 「Partners Expansion」  Location： U.S. New Jersey  Employee： 13 CDMO ＋  Business portfolio： Contents Existing PSG Intermediate

  13. Slide 13: HS

    HS Quarterly Results YoY Comparison Net sales EBITDA, OP (¥ billion) (¥ billion) (¥ billion) 10 4 FY24_Q1 FY25_Q1 Change Net sales 7.34 7.99 +0.65 +8.9% 8.0 Sterilization/ 7.6 5.77 6.06 +0.29 +5.0% 7.3 7.5 operation-related 7.1 Home-visiting, 1.57 1.93 +0.36 +23.2% 1.9 welfare 1.6 1.6 1.9 Ratio 12.4

  14. Slide 14: Cash and Deposits / Interest-bearing Debts

    Cash and Deposits / Interest-bearing Debts (¥ billion) FY2024 FY2025 Cash and deposits 47.0 Short-term debts 37.3 40.9 36.1 30.9 Bonds due within Cash and one year deposits Interest- bearing Long-term debts debts Interest-bearing 10.0 10.0 10.1 debts 20.0 20.0 Lease debts 10.0 29.0 29.2 Bonds payabl

  15. Slide 15: Contact information

    【Contact information】 IR/SR Department Email : ir@hugp.com Disclaimer regarding forward-looking statement: The performance forecast provided in this document is prepared by the management based on currently available information and various hypotheses and ideas including significant risks or uncerta

H.U. Group Holdings — Q1 FY2025 Earnings Presentation on 6ix